Pacira Pharmaceuticals (PCRX) Posts Q4 Loss of 72c/Share

Pacira Pharmaceuticals (NASDAQ: PCRX) reported Q4 EPS of ($0.72), $0.18 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $4.23 million versus the consensus estimate of $4.05 million.

For earnings history and earnings-related data on Pacira Pharmaceuticals (PCRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Sun Communities names Ileana McAlary as general counsel and EVP
• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight